iBio (IBIO) Registration Filing summary

Company overview and business model

• Operates as a biotechnology company leveraging AI and machine learning to discover novel biologics, focusing on hard-to-develop molecules and bi-specifics for preclinical drug discovery.

• Strategic pillars include AI-driven epitope discovery, strategic partnerships, technology licensing, and advancing in-house programs in oncology, obesity, and cardiometabolic diseases.

• EngageTx™ technology targets bi-specific molecules, aiming to improve preclinical safety and agility.

Financial performance and metrics

• Closed a private placement in April 2024, raising gross proceeds of $15.1 million and net proceeds of $14.1 million after expenses.

• As of June 26, 2024, had 8,623,676 shares of common stock outstanding and no preferred stock issued.

• Net tangible book value as of March 31, 2024, was $2.29 per share; pro forma as adjusted after recent transactions and the offering would be $1.75 per share.

• Aggregate market value of outstanding common stock held by non-affiliates is approximately $22.1 million.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used primarily for working capital and general corporate purposes, including potential acquisitions, licensing, investments in assets, technologies, product candidates, or intellectual property, and repurchasing securities.

• Management retains broad discretion over capital allocation.